Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661498 · ClinicalTrials.gov registry record · Phase 4
Indomethacin for Biliary ERCP Patients
A Phase 4 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 4
- Development phase
- 860
- Enrollment target
NCT07661498 is a Phase 4 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 860 participants.
The verdict
NCT07661498, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 860 participants
- Enrollment target
Study Summary
This study is a randomized clinical trial evaluating the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients undergoing biliary ERCP who have a history of prior biliary sphincterotomy. While rectal indomethacin has demonstrated benefits in preventing post-ERCP pancreatitis in high-risk patients, its utility in this specific patient subgroup remains unclear. This trial aims to determine whether prophylactic administration of indomethacin offers a measurable benefit over no intervention in this lower-risk population. Eligible patients will be identified prior to their scheduled biliary ERCP and screened for inclusion criteria. Following informed consent, participants will be randomized to receive either rectal indomethacin or no indomethacin prior to the procedure.
Interventions
- DRUG indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07661498
The ClinicalTrials.gov registry entry for NCT07661498 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which indomethacin is the first listed.
NCT07661498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07661498 about?
NCT07661498 is a clinical study titled "Indomethacin for Biliary ERCP Patients". This study is a randomized clinical trial evaluating the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients undergoing biliary ERCP who have a history of prior biliary sphincterotomy. While rectal indomethacin has demonst...
What is the current status of trial NCT07661498?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 860 participants. The study started on 2026-07. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07661498?
The interventions under investigation include: indomethacin (DRUG).
Who is sponsoring clinical trial NCT07661498?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.